Delta Air Lines, Skypeople, Ionis Pharmaceuticals Stocks Moving Today

Political tensions are weighing on the stock market, as traders digest the latest White House policy announcements. Among specific equities in focus are travel interest Delta Air Lines, Inc. (NYSE:DAL), beverage stock Skypeople Fruit Juice Inc (NASDAQ:SPU), and biotech concern Ionis Pharmaceuticals Inc (NASDAQ:IONS). Here's a quick look at what's moving shares of DAL, SPU, and IONS.

Forecast Cut, Travel Ban See Delta Air Lines Lose Support

Shares of DAL are down 3.3% at $48.46, after the company cut its current-quarter margin forecast, citing a rise in fuel costs. The stock is also taking a hit on news of President Donald Trump's revised travel ban, which was signed earlier today. Delta Air Lines, Inc. has been butting up against resistance below the $52 mark for roughly three months, and is now desperate to find a foothold at the year-over-year breakeven level after giving up support at the 80-day moving average. There could be even more trouble ahead should analysts downwardly revise their opinions. At the moment, nine out of 11 firms following DAL call the stock a "buy" or better, without a single "sell" rating on the books. 

Aigo Integrity Alliance Pact Sends Skypeople Shares Soaring

SPU is soaring 19.4% to $6.01 -- making it one of the top performers on the Nasdaq -- following news the company signed a one-year agreement to join China Aigo O2O Technology Inc.'s Aigo Integrity Alliance. Skypeople Fruit Juice Inc has roughly doubled year-over-year, following a volatile 12 months that included a short-lived spike as high as $20.95 in late July. Still, today's pop is not enough to put the shares above their 40-day moving average, which has been pressuring SPU lower since New Year's. Perhaps more good news for the company would inspire the brokerage bunch to take an interest, as not a single analyst currently covers the stock.

Drug-Study Dropouts Dent Ionis Pharmaceuticals Stock

Positive results in a Phase 3 study of IONS' familial chylomicronemia syndrome (FCS) drug, volanesorsen, are being overshadowed by the fact five participants discontinued their participation in the trial due to a decline in platelet levels. As such, the stock is trading 6.9% lower at $50.95, after coming within pennies of a new annual high on Friday. Today's pullback may come as a relief to options traders, who have been betting heavily against IONS in recent weeks. In fact, the stock's 10-day put/call volume ratio of 3.02 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows puts bought to open at triple the rate of calls. Moreover, this reading ranks just 6 percentage points from an annual high.